ITEMS IN AFP WITH KEYWORD:
Inborn errors of metabolism (IEM) are genetic conditions that can be detected as early as preconception carrier screening. The IEM disorders can present at any time during life, but most are detected in newborns. Newborns presenting with the disorder require immediate consult with a metabolic specialist. Long-term treatments are effective for some IEM disorders.
May 1, 2018 Issue
Clinical and Personal Utility of Genetic Risk Testing [Curbside Consultation]
On April 6, 2017, the U.S. Food and Drug Administration (FDA) approved marketing of the 23andMe Personal Genome Service, the first direct-to-consumer genetic test. This test uses genomic DNA collected from mail-in saliva collection kits to provide information on a patient's genetic risk of certain medical diseases or conditions.
Dec 15, 2017 Issue
Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing [Editorials: Controversies in Family Medicine]
Precision medicine is ultimately only a tool, and just as it might be used to facilitate better outcomes, if adopted prematurely, it may paradoxically increase inappropriate care. Therefore, primary care physicians must wait for carefully conducted randomized studies to demonstrate benefits before embracing it.
Dec 15, 2017 Issue
Is "Precision Medicine" Ready to Use in Primary Care Practice? Yes: It Offers Patients More Individualized Ways of Managing Their Health [Editorials: Controversies in Family Medicine]
The question that primary care physicians should be considering is not whether precision medicine is ready for “prime time” in their practices. Rather, they should be considering how they will adjust their practice patterns to the changing landscape of medicine to maximize patient benefit while minimizing potential harms, including costs.
Each year, 4 to 5 million newborns receive state-mandated screening in an effort to detect and treat serious disorders before harmful effects can occur. Learn about the recommended screening tests and resources for determining the next steps if a newborn screening result is positive.
A newborn presents with bilateral wrist flexion and shortened forearms.
Patients informed via genetic test results that they were at increased risk of disease did not subsequently alter their behaviors. For example, persons at increased risk of diabetes mellitus or hypertension were no more likely to change their diet or increase their physical activity. Fancy tests do not appear to be motivators for behavior change.
Social media and the Internet can be valuable resources for patients, especially for those who have been estranged from their families.
Clinical pharmacogenetics, the use of genetic data to guide drug therapy decisions, is increasingly being used for medications commonly prescribed by family physicians. Two common gene-drug pairs are discussed to illustrate how pharmacogenetic data can be applied clinically.